Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Hypoxia as a Factor Involved in the Regulation of the apoA-1, ABCA1, and Complement C3 Gene Expression in Human Macrophages.

Bogomolova AM, Shavva VS, Nikitin AA, Nekrasova EV, Dizhe EB, Larionova EE, Kudriavtsev IV, Orlov SV.

Biochemistry (Mosc). 2019 May;84(5):529-539. doi: 10.1134/S0006297919050079.

PMID:
31234767
2.

[Characterization of Distal and Proximal Alternative Promoters of the Human ApoA-I Gene].

Mogilenko DA, Shavva VS, Dizhe EB, Orlov SV.

Mol Biol (Mosk). 2019 May-Jun;53(3):485-496. doi: 10.1134/S0026898419030121. Russian.

3.

Development of a motor and somatosensory evoked potentials-guided spinal cord Injury model in non-human primates.

Baklaushev VP, Durov OV, Kim SV, Gulaev EV, Gubskiy IL, Konoplyannikov MA, Zabozlaev FG, Zhang C, Agrba VZ, Orlov SV, Lapin BA, Troitskiy AV, Averyanov AV, Ahlfors JE.

J Neurosci Methods. 2019 Jan 1;311:200-214. doi: 10.1016/j.jneumeth.2018.10.030. Epub 2018 Oct 25.

PMID:
30393204
4.

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.

Lavdovskaia ED, Iyevleva AG, Sokolenko AP, Mitiushkina NV, Preobrazhenskaya EV, Tiurin VI, Ivantsov AO, Bizin IV, Stelmakh LV, Moiseyenko FV, Karaseva NA, Orlov SV, Moiseyenko VM, Korzhenevskaya MA, Zaitsev IA, Kozak AR, Chistyakov IV, Akopov AL, Volkov NM, Togo AV, Imyanitov EN.

Oncol Res Treat. 2018;41(10):634-642. doi: 10.1159/000491441. Epub 2018 Aug 27.

PMID:
30145586
5.

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.

Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN.

Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30.

PMID:
30071258
6.

In Vivo Experimental Study of Biological Compatibility of Tissue Engineered Tracheal Construct in Laboratory Primates.

Gilevich IV, Sotnichenko AS, Karal-Ogly DD, Gubareva EA, Kuevda EV, Polyakov IS, Lapin BA, Orlov SV, Porkhanov VA, Chekhonin VP.

Bull Exp Biol Med. 2018 Apr;164(6):770-774. doi: 10.1007/s10517-018-4077-y. Epub 2018 Apr 16.

PMID:
29658077
7.

Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPARγ.

Shavva VS, Bogomolova AM, Efremov AM, Trofimov AN, Nikitin AA, Babina AV, Nekrasova EV, Dizhe EB, Oleinikova GN, Missyul BV, Orlov SV.

Eur J Cell Biol. 2018 Apr;97(3):204-215. doi: 10.1016/j.ejcb.2018.03.001. Epub 2018 Mar 9.

PMID:
29550264
8.

Tumor necrosis factor α stimulates endogenous apolipoprotein A-I expression and secretion by human monocytes and macrophages: role of MAP-kinases, NF-κB, and nuclear receptors PPARα and LXRs.

Shavva VS, Mogilenko DA, Nekrasova EV, Trulioff AS, Kudriavtsev IV, Larionova EE, Babina AV, Dizhe EB, Missyul BV, Orlov SV.

Mol Cell Biochem. 2018 Nov;448(1-2):211-223. doi: 10.1007/s11010-018-3327-7. Epub 2018 Feb 13.

PMID:
29442267
9.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM.

Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8.

10.

FOXO1 and LXRα downregulate the apolipoprotein A-I gene expression during hydrogen peroxide-induced oxidative stress in HepG2 cells.

Shavva VS, Bogomolova AM, Nikitin AA, Dizhe EB, Oleinikova GN, Lapikov IA, Tanyanskiy DA, Perevozchikov AP, Orlov SV.

Cell Stress Chaperones. 2017 Jan;22(1):123-134. doi: 10.1007/s12192-016-0749-6. Epub 2016 Nov 28.

11.

Evaluation of the influence of decellularization on the changes in biomechanical properties of primate lungs.

Kuevda EV, Gubareva EA, Krasheninnikov SV, Grigoriev TE, Gumenyuk IS, Sotnichenko AS, Gilevich IV, Karal-Ogly DD, Orlov SV, Chvalun SN, Redko AN, Alekseenko SN, Macciarini P.

Dokl Biochem Biophys. 2016 Sep;470(1):375-378. Epub 2016 Nov 6.

PMID:
27817028
12.

Insulin-Mediated Downregulation of Apolipoprotein A-I Gene in Human Hepatoma Cell Line HepG2: The Role of Interaction Between FOXO1 and LXRβ Transcription Factors.

Shavva VS, Bogomolova AM, Nikitin AA, Dizhe EB, Tanyanskiy DA, Efremov AM, Oleinikova GN, Perevozchikov AP, Orlov SV.

J Cell Biochem. 2017 Feb;118(2):382-396. doi: 10.1002/jcb.25651. Epub 2016 Sep 30.

PMID:
27404023
13.

[The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors].

Ivanets NN, Kinkulkina MA, Tikhonova YG, Avdeeva TI, Ragimov AA, Dashkova NG, Kuznetsov OE, Matveev AV, Iziumina TA, Orlov SV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(2):46-51. doi: 10.17116/jnevro20161162146-51. Russian.

PMID:
27029447
14.

PPARγ Represses Apolipoprotein A-I Gene but Impedes TNFα-Mediated ApoA-I Downregulation in HepG2 Cells.

Shavva VS, Mogilenko DA, Bogomolova AM, Nikitin AA, Dizhe EB, Efremov AM, Oleinikova GN, Perevozchikov AP, Orlov SV.

J Cell Biochem. 2016 Sep;117(9):2010-22. doi: 10.1002/jcb.25498. Epub 2016 Feb 8.

PMID:
26813964
15.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA.

J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.

16.

[Preclinical study of AV0012 early stage inhibitor of hepatitis C virus infection: I. In vitro ADME and pharmacokinetics].

Ivashchenko AV, Iamanushkin PM, Mit'kin OD, Ezhova EV, Korzinov OM, Shevkun NA, Koriakova AG, Karapetian RN, Bychko VV, Ivashchenko AA, Agrba VZ, Lapin BA, Orlov SV.

Eksp Klin Farmakol. 2014;77(4):33-41. Russian.

PMID:
25076758
17.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S.

Lung Cancer. 2014 Sep;85(3):429-34. doi: 10.1016/j.lungcan.2014.06.008. Epub 2014 Jul 5.

PMID:
25047675
18.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M.

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.

PMID:
24933332
19.

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

Iyevleva AG, Mitiushkina NV, Karaseva NA, Orlov SV, Volodina LN, Kulikova YE, Lozhkina AM, Ivantsov AO, Tiurin VI, Togo AV, Imyanitov EN.

J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106. No abstract available.

20.

[Cerebrovascular diseases and metabolic syndrome].

Tanashian MM, Lagoda OV, Orlov SV, Telenkova NG, Maksiutkina LN, Petrukhina SIu.

Ter Arkh. 2013;85(10):34-42. Russian.

PMID:
24437216

Supplemental Content

Loading ...
Support Center